Vaccines against human diarrheal pathogens Current status and perspectives

被引:17
作者
Boehles, Nathalie [1 ]
Busch, Kim [1 ]
Hensel, Michael [1 ]
机构
[1] Univ Osnabruck, Abt Mikrobiol, Osnabruck, Germany
关键词
diarrheal diseases; human pathogen; oral vaccine; recombinant vaccine; Vibrio cholerae; Shigella spp; Campylobacter spp; rotavirus; SHIGELLA-FLEXNERI; 2A; ENTEROTOXIGENIC ESCHERICHIA-COLI; O-SPECIFIC POLYSACCHARIDE; VIBRIO-CHOLERAE O139; ROTAVIRUS VACCINATION; ANTIGENIC VARIATION; MASS VACCINATION; IMMUNE-RESPONSES; EFFICACY TRIAL; ORAL VACCINE;
D O I
10.4161/hv.29241
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 [微生物学]; 090105 [作物生产系统与生态工程];
摘要
Worldwide, nearly 1.7 billion people per year contract diarrheal infectious diseases (DID) and almost 760 000 of infections are fatal. DID are a major problem in developing countries where poor sanitation prevails and food and water may become contaminated by fecal shedding. Diarrhea is caused by pathogens such as bacteria, protozoans and viruses. Important diarrheal pathogens are Vibrio cholerae, Shigella spp. and rotavirus, which can be prevented with vaccines for several years. The focus of this review is on currently available vaccines against these three pathogens, and on development of new vaccines. Currently, various types of vaccines based on traditional (killed, live attenuated, toxoid or conjugate vaccines) and reverse vaccinology (DNA/mRNA, vector, recombinant subunit, plant vaccines) are in development or already available. Development of new vaccines demands high levels of knowledge, experience, budget, and time, yet promising new vaccines often fail in preclinical and clinical studies. Efficacy of vaccination also depends on the route of delivery, and mucosal immunization in particular is of special interest for preventing DID. Furthermore, adjuvants, delivery systems and other vaccine components are essential for an adequate immune response. These aspects will be discussed in relation to the improvement of existing and development of new vaccines against DID.
引用
收藏
页码:1522 / 1535
页数:14
相关论文
共 136 条
[1]
Afzal MA, 2007, WHO WORSH TAINIGN, P8
[2]
Wanted, dead or alive: New viral vaccines [J].
Amanna, Ian J. ;
Slifka, Mark K. .
ANTIVIRAL RESEARCH, 2009, 84 (02) :119-130
[3]
[Anonymous], 2010, Wkly Epidemiol Rec, V85, P117
[4]
[Anonymous], 2006, Working Together for Health
[5]
Projected health and economic impact of rotavirus vaccination in GAVI-eligible countries: 2011-2030 [J].
Atherly, Deborah E. ;
Lewis, Kristen D. C. ;
Tate, Jacqueline ;
Parashar, Umesh D. ;
Rheingans, Richard D. .
VACCINE, 2012, 30 :A7-A14
[6]
Shigella sonnei vaccine candidates WRSs2 and WRSs3 are as immunogenic as WRSS1, a clinically tested vaccine candidate, in a primate model of infection [J].
Barnoy, S. ;
Baqar, S. ;
Kaminski, R. W. ;
Collins, T. ;
Nemelka, K. ;
Hale, T. L. ;
Ranallo, R. T. ;
Venkatesan, M. M. .
VACCINE, 2011, 29 (37) :6371-6378
[7]
Characterization of WRSs2 and WRSs3, new second-generation virG(icsA)-based Shigella sonnei vaccine candidates with the potential for reduced reactogenicity [J].
Barnoy, S. ;
Jeong, K. I. ;
Helm, R. F. ;
Suvarnapunya, A. E. ;
Ranallo, R. T. ;
Tzipori, S. ;
Venkatesan, M. M. .
VACCINE, 2010, 28 (06) :1642-1654
[8]
Cholera-Like Enterotoxins and Regulatory T cells [J].
Basset, Christelle ;
Thiam, Fatou ;
Di Martino, Cyrille ;
Holton, John ;
Clements, John D. ;
Kohli, Evelyne .
TOXINS, 2010, 2 (07) :1774-1795
[9]
Further characterization of Shigella sonnei live vaccine candidates WRSs2 and WRSs3-plasmid composition, invasion assays and Sereny reactions [J].
Bedford, Lisa ;
Fonseka, Suramya ;
Boren, Tara ;
Ranallo, Ryan T. ;
Suvarnapunya, Akamol E. ;
Lee, James E. ;
Barnoy, Shoshana ;
Venkatesan, Malabi M. .
GUT MICROBES, 2011, 2 (04) :244-251
[10]
Evaluation of DNA encoding acidic ribosomal protein P2 of Cryptosporidium parvum as a potential vaccine candidate for cryptosporidiosis [J].
Benitez, Alvaro ;
Priest, Jeffrey W. ;
Ehigiator, Humphrey N. ;
McNair, Nina ;
Mead, Jan R. .
VACCINE, 2011, 29 (49) :9239-9245